Dietary and Lifestyle Interventions for Steatotic Liver Disease Associated with Metabolic Dysfunction

Shilpa Madhukarrao Mahajan; Vaishnavi Onkar Umretkar; Nitin Shalikram Chapekar; Vishakha Vidhyasagar Oimbe; Darshana Niranjan Shende

doi:10.36948/ijfmr.2025.v07i05.57690

Dietary and Lifestyle Interventions for Steatotic Liver Disease Associated with Metabolic Dysfunction

Author(s)	Ms. Shilpa Madhukarrao Mahajan, Ms. Vaishnavi Onkar Umretkar, Mr. Nitin Shalikram Chapekar, Ms. Vishakha Vidhyasagar Oimbe, Ms. Darshana Niranjan Shende
Country	India
Abstract	Abstract: The Steatotic liver disease associated with metabolic dysfunction (MASLD) is one of several disorders tied to metabolic imbalances. Hepatic steatosis combined with at least having a cardiometabolic condition such as type 2 diabetes, overweight , high blood pressure, or lipid disorders chracterizes this exteamly common metabolic illness which was formarly known as non alcoholic fatty liver disease (NAFLD) are nearly associated with the metabolic disorder, which includes liver damage that change over time. The mainstay of managing MASLD is altering one's lifestyle to improve insulin resistance and metabolic balance. The key elements of MASLD treatment are customized lifestyle changes and a Mediterranean-style diet. It is advised to actively treat all metabolic co-morbidities and do a thorough assessment of alcohol consumption. The condition in which liver become inflamed is known as MASH and increased fibrogenesis it may proceed for severe liver disease. The FDA and EMA have classified this community as "at-risk MASH," meaning they are eligible for pharmacological treatment. To treat MASH, reverse fibrosis, or both, there is currently a strong pharmaceutical pipeline spanning numerous novel targets. Certain of these treatments have positive benefits on lipid profiles, weight loss, and glycaemic management in addition to the liver. As an alternative end-point, reversal of fibrosis by one stage or resolution of MASH without fibrosis worsening must be supported by overall survival gains for "at-risk" MASH. This is a summary of information, currently available on lifestyle modifications in MASLD and pharmaceutical therapies for fibrosis MASH that have advanced to phase II and phase III clinical studies.
Keywords	Keyword: MASLD, MASH, Fibrosis, lifestyle changes and a Mediterranean-style diet.
Field	Medical / Pharmacy
Published In	Volume 7, Issue 5, September-October 2025
Published On	2025-10-17
DOI	https://doi.org/10.36948/ijfmr.2025.v07i05.57690

View / Download PDF File

E-ISSN 2582-2160

doi

CrossRef DOI is assigned to each research paper published in our journal.

IJFMR DOI prefix is
10.36948/ijfmr

Downloads

Research Paper Format Copyright Permission Form and Undertaking Form Cover Page Vol 8 Isu 2 Cover Page Vol 8 Isu 1 Cover Page Vol 7 Isu 6

All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.

CC-BY-SA

About IJFMR Fees & Payment Current Issue Publication Archive	Submit Research Paper Track Submission Status Publication Guidelines Publication Ethics Peer Review & Plagiarism	Join as a Reviewer Editors & Reviewers Reviewer Referral Program Get Reviewer Membership Certi.	Website/Journal Policies Usage Policy Content Policies Privacy Policy

Contact Us		+91-9687-828-838	editor@ijfmr.com

International Journal For Multidisciplinary Research

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Dietary and Lifestyle Interventions for Steatotic Liver Disease Associated with Metabolic Dysfunction

Share this